Could Amgen test Enbrel or other anti-TNF drugs against COVID-19? CEO Bradway drops a hint Rural health systems among top recipients of PPP loans Report: Telehealth claims lines up 8,336% in April due to COVID-19 French biotech Osivax nabs funding boost for universal flu, coronavirus vaccine work Intermountain, Stanford Children's CEOs say hospitals need to get comfortable being a 'frenemy' AstraZeneca, Lilly, Sanofi and others raise prices to start July: report Healthcare roundup: Epidemiologists call for 'Universal Pandemic Precautions' for patients and healthcare workers Biopharma roundup: CEPI expands Clover vaccine deal with $66M upfront; Cipla undercuts rivals on remdesivir cost With COVID-19 vaccines coming, SiO2 injects $163M into vial production plant Groups urge Congress to take action on patient identifier as COVID-19 raises the stakes Featured Story | By Arlene Weintraub As Amgen prepares for clinical trials of its psoriasis drug Otezla in COVID-19, it might also investigate the potential for TNF inhibitors like its blockbuster anti-inflammatory Enbrel to fight the virus, CEO Robert Bradway said. Recent reports of favorable COVID outcomes in patients taking anti-TNF drugs may be fueling the interest. read more |
| |
|---|
|
| | [Webinar] Zero Deviation Mindset: Achieving Agility in Cell Therapy Supply Chains Tuesday, July 21 | 10am ET / 7am PT Join Thermo Fisher Scientific and Pluristem Therapeutics as we discuss lessons learned in developing the just-in-time supply chain for their phase III hip fracture study, and how these lessons are being used in their current efforts to treat severe COVID-19 cases complicated by Acute Respiratory Distress Syndrome (ARDS) in the United States. Register Now. |
Top Stories By Tina Reed Among the recipients in healthcare granted the most loan funding through the Paycheck Protection Program: rural health systems. read more By Paige Minemyer Telehealth claims lines have seen massive spikes due to the COVID-19 pandemic and a new report shows just how big those increases are. read more By Ben Adams Little Lyon biotech Osivax has grabbed €30 million ($33.8 million) for its universal coronavirus and influenza inoculations. read more By Tina Reed Here's the big lesson health systems need to take away from the COVID-19 pandemic, according to Intermountain CEO Marc Harrison, M.D., and Stanford Children's Health CEO Paul King. read more By Eric Sagonowsky A pandemic hasn’t stopped some drugmakers from pushing through their traditional mid-year price hikes. But though pharmas big and small have raised prices so far this month, the current round of increases is far smaller than January's. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner CEPI expanded a deal with Clover Biopharmaceuticals and provided $66M upfront to rush the company's vaccine into preclinical tests. Amgen could pivot its TNF inhibitor Enbrel to attack COVID-19. Cipla undercut rivals' prices as it pushed its generic remdesivir to market Wednesday. Plus, the NIAID launched a new clinical trials network. read more By Fraiser Kansteiner Hundreds of millions of COVID-19 vaccine doses require hundreds of millions of vials, and the U.S. government handed $143 million to materials manufacturer SiO2 to make sure that supply keeps coming. Now, the company is shelling out $163 million to upgrade its Auburn, Alabama, glass vial site and scale up production. read more By Heather Landi Patient identity and matching problems are not new to healthcare but the current pandemic has exposed long-standing deficiencies in the underlying technology infrastructure, healthcare leaders say. read more |
